Comparing two drug combinations for stem cell transplant
Treatments studied
Part of Immune system & allergy, Lungs & breathing clinical trials.
This trial tests two different combinations of medicines to prevent graft-versus-host disease (when donor cells attack your body) after a stem cell transplant. The goal is to see which approach works better for people with certain blood cancers or lymphomas.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have a blood cancer such as acute leukemia, chronic myelogenous leukemia, myelodysplasia, chronic myelomonocytic leukemia, or certain types of lymphoma.
- You are planning to receive a reduced-intensity conditioning stem cell transplant using cells from a related or unrelated donor.
- Your heart, kidney, lung, and liver functions meet specific minimum levels.
- You have not had a prior stem cell transplant or used ruxolitinib before.
- You do not have an active infection, uncontrolled hepatitis, or uncontrolled HIV.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of medications given before and after a stem cell transplant from a family member to prevent graft-versus-host disease (GVHD)—a condition where the new cells attack your body. The study includes a newer drug called ivarmacitinib that may help reduce this serious side effect.
This trial tests a new approach to prevent graft-versus-host disease (GVHD) after a stem cell transplant from a matched donor. It is for people aged 60 or older with a blood cancer or serious blood disorder who are getting a reduced-intensity conditioning regimen.
This trial tests if a drug combo (cyclophosphamide, sirolimus, and ruxolitinib) works better than another combo (cyclophosphamide, sirolimus, and mycophenolate mofetil) to prevent graft versus host disease in people getting a stem cell transplant for certain blood cancers.
This trial tests a three-drug combination (cyclophosphamide, tacrolimus, and ruxolitinib) to prevent graft-versus-host disease (GVHD) after a stem cell transplant. It is for people with certain blood cancers who have a matched donor and can tolerate high-dose chemotherapy.
This trial tests two different chemotherapy and radiation plans (conditioning regimens) given before a stem cell transplant from a matched donor. Both are followed by the same drugs to prevent graft-versus-host disease. The goal is to find which regimen works better for people with blood cancers.
This trial tests a combination of three drugs (vedolizumab, cyclophosphamide, and tacrolimus) to prevent graft-versus-host disease, a common complication after a donor stem cell transplant. It is for people with certain blood cancers who are getting a reduced-intensity transplant.
Hear when a new Graft-versus-host Disease (GVHD) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.